Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H23N5O5 |
Molecular Weight | 449.4592 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(N)=C2C=C(CCC3=CC=C(C=C3)C(=O)NC(CC(=C)C(O)=O)C(O)=O)C=CC2=N1
InChI
InChIKey=NAWXUBYGYWOOIX-UHFFFAOYSA-N
InChI=1S/C23H23N5O5/c1-12(21(30)31)10-18(22(32)33)26-20(29)15-7-4-13(5-8-15)2-3-14-6-9-17-16(11-14)19(24)28-23(25)27-17/h4-9,11,18H,1-3,10H2,(H,26,29)(H,30,31)(H,32,33)(H4,24,25,27,28)
Molecular Formula | C23H23N5O5 |
Molecular Weight | 449.4592 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:12:56 UTC 2023
by
admin
on
Sat Dec 16 12:12:56 UTC 2023
|
Record UNII |
8Y3RH62XPB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8Y3RH62XPB
Created by
admin on Sat Dec 16 12:12:56 UTC 2023 , Edited by admin on Sat Dec 16 12:12:56 UTC 2023
|
PRIMARY | |||
|
238074-89-0
Created by
admin on Sat Dec 16 12:12:56 UTC 2023 , Edited by admin on Sat Dec 16 12:12:56 UTC 2023
|
PRIMARY | |||
|
CH-1504
Created by
admin on Sat Dec 16 12:12:56 UTC 2023 , Edited by admin on Sat Dec 16 12:12:56 UTC 2023
|
PRIMARY | Official Title: A Phase II, Multi-center, Randomized, Double-blind, Methotrexate Controlled Study to Assess the Clinical Efficacy, Safety, and Tolerability of CH-1504 in Subjects With Active Rheumatoid ArthritisPurpose: The purpose of this trial is to assess the clinical effect of CH-1504 at doses of 0.25, 0.5 and 1.0 mg per day in patients with active rheumatoid arthritis by determining the proportion of patients achieving an American College of Rheumatology (ACR) 20% improvement response. | ||
|
9846537
Created by
admin on Sat Dec 16 12:12:56 UTC 2023 , Edited by admin on Sat Dec 16 12:12:56 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Demographic characteristics were similar in all treatment groups: mean age 54.3 +/- 11.4 years, female sex 87%, mean baseline DAS28 6.6 +/- 0.9. At Week 12, CH-1504 demonstrated comparable efficacy compared to MTX as measured by ACR20, DAS28, and ACR composite core-set measures, including tender and swollen joints. No dose-response relationship was observed. Adverse events across treatment groups were mild. Liver enzyme levels increased from baseline to Week 16 in the MTX group, with qualitatively lesser increases in the CH-1504 groups. Two patients in the MTX group withdrew because of gastrointestinal-related adverse events. CH-1504 appeared safe and well tolerated at all dose levels. CONCLUSION: CH-1504 has comparable efficacy to MTX and is safe and well tolerated. Metabolically stable antifolates are a promising therapeutic option that warrants further study.
|
||
|
ACTIVE MOIETY |
Class: Anti-neoplastic; Mechanism of Action: Tetrahydrofolate dehydrogenase inhibitor; Highest Development Phases: Discontinued for Cancer, Inflammatory bowel diseases, Psoriasis, and Rheumatoid arthritis; Most Recent Events: 24 Jun 2014 Chelsea Therapeutics has been acquired and merged into Lundbeck A/S, 22 Oct 2009 Interim efficacy and adverse events data from a phase II trial in Rheumatoid arthritis presented at the the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2009), 18 Mar 2009 Interim efficacy & adverse events data from a phase II trial in Rheumatoid arthritis released by Chelsea Therapeutics
|